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Genetic Analysis on HLA Loci in Japanese Patients with
Abdominal Aortic Aneurysm
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Purpose: autoimmunity has been proposed as one of the pathogenesis of abdominal aortic aneurysm (AAA). There is also a
likelihood that when aorto-iliac occlusive disease (AIOD) coexists with AAA, some other occlusive atherosclerotic diseases,
such as ischemic heart disease and cerebrovascular disease, may develop, leading to a very poor long-term prognosis.
Previous studies using serological HLA typing showed that HLA-DR15 was a risk factor for AAA. In this study, we
performed HLA-DNA typing by PCR to clarify the relationship between AAA and HLA genotypes in Japanese patients
with AAA. In addition, we analyzed whether HLA genotypes are involved in the pathogenesis of AIOD.
Results: we examined 78 HLA genotypes of class I (HLA-A and -B) and class II (HLA-DR) and found that 60.4 and 30.4%
of 49 AAA patients had HLA-A2 and HLA-B61, respectively. These frequencies were significantly higher than those in
control individuals (HLA-A2, p5 0.05; HLA-B61, p5 0.005). We also found that 55.6% of nine AAA patients with
AIOD had both HLA-B52 and HLA-DR B11502. In contrast, only 10.0% each of 40 AAA patients without AIOD showed
HLA-B53 or HLA-DR B11502.
Conclusions: this study showed that HLA A-2 and HLA B-61, but not HLA DR-15, were important genetic risk factors
for the development of AAA among the Japanese population. We also found high frequencies of HLA-B52 and HLA-DR
B11502 in the AAA patients with AIOD than in those without, although this must be confirmed using a larger number of
AAA patients with AIOD.
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Introduction
It has been suggested that abdominal aortic aneurysm
(AAA) is a multifactorial genetic disease autoimmune
(AI) characteristics.1±3 The human HLA region is
extremely polymorphic,4 certain of which may predis-
pose to particular AI diseases.5 Class-I (HLA-A, and
-B) are recognized by receptors on CD8-positive sup-
pressor T cells, while class-II molecules (HLA-DR) are
recognized by receptors on CD4-positive helper T cells
when attacking and eliminating foreign substances.
Through this mechanism, HLA molecules are
involved in not only the recognition of self-non-self
but also self-defense and pathogenesis of diseases.
Previous studies have suggested that HLA-DR15 was
associated with AAA.6±9 Here, we extend these find-
ings by examining the relationship between HLA type
and AAA in Japanese patients with and without co-
existing aorto-iliac occlusive disease (AIOD).10
Patients and Methods
Forty-nine patients (41 men, eight women, mean age
(range) 69.3 7.7 (range 47±83) years) with infra-renal
AAA were randomly selected from 426 patients
undergoing surgical repair between 1974 and 2000.
AIOD was based on angiographic findings (475%
stenosis, 450% stenosis 45 cm below the common
iliac artery, or an ankle pressure index of less
than 0.6). Peripheral blood was withdrawn from the
patients after obtaining informed consent, and high-
molecular-weight DNA was extracted.11 The control
group comprised 237 healthy Japanese volunteers
(168 men, 67 women, of mean age of 45 years).12
HLA-A, -B, -DR and -DRb1 sequences were amplified
by PCR using primers specific to each gene and
analyzed by agarose gel electrophoresis. Statistical
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analysis of the number and percentage of subjects
expressing specific genes was performed using the
chi-squared test. A probability value of p-corrected
(p5 0.05) was considered significant.
Results
HLA class I HLA-A2 was found in 29 AAA patients
(60.4%) and 101 controls (42.6%) ( p 0.0358). HLA-
B61 was found in 14 AAA patients (30.4%) and 27
controls (11.4%) ( p 0.0018). There were no significant
difference between AAA patients and controls with
regard to any other class I HLA genes or class-II HLA
genes (Tables A-1±A-4). Five AAA patients with co-
existing AIOD (AIOD-positive group) had both HLA
B52 and HLA-DR B11502 genotypes. On the other
hand, four each of 40 AAA patients without AIOD
(AIOD-negative group) had HLA-B52 or HLA-DR
B11502. The frequency of HLA-B52 in AIOD-positive
group was higher than that in AIOD-negative group
( p 0.032), and that of HLA-DR B11502 in positive
group was significantly higher than that in negative
group ( p 0.007) (Table B).
Table A-1. Phenotype frequency of HLA-A.
Antigens Patients PF GF Controls PF GF X2 X2c p value p-corrected
value
Odds ratio
1 1 2.1 1.1 3 1.3 0.6 0.2233 0.0435 0.6365 0.8349 1.7423
2 29 60.4 37.1 101 42.6 24.2 5.0984 4.4061 0.0240 0.0358 2.0552
3 1 0.4 0.2
11 6 12.5 6.5 45 19.0 10.0 0.7440 0.2850 0.3884 0.6095
24 32 66.7 42.3 148 62.5 38.6 1.1434 0.1510 0.5805 0.6976 1.2027
26 13 27.1 14.6 53 22.4 11.9 0.3054 0.2700 0.4800 0.6035 1.2890
30 1 0.4 0.2 0.4998
31 6 12.5 6.5 32 13.5 6.8 0.0347 0.0022 0.8523 0.9628 0.9151
33 9 18.8 9.9 43 18.1 9.7 0.0098 0.0011 0.9210 0.9158 1.0411
Total 48 237
PF, phenotype frequency; GF, gene frequency.
Table A-2. Phenotype frequency of HLA-B.
Antigens Patients PF GF Controls PF GF X2 X2c p value p-corrected
value
Odds ratio
7 5 10.9 5.6 31 13.1 6.9 0.1700 0.0290 0.6805 0.8650 0.8104
13 1 2.2 1.1 26 11.0 5.7 3.4540 2.5100 0.0631 0.1131 0.1803
62 16 34.8 19.3 51 21.5 11.4 3.7501 3.0524 0.0530 0.0806 1.9450
75 4 1.7 0.9
71 1 0.4 0.2
35 4 8.7 4.4 36 15.2 8.1 1.3390 0.8571 0.2473 0.3546 0.5317
37 5 2.1 1.1
38 1 0.4 0.2
39 5 10.9 5.6 26 11.0 5.7 0.0000 0.0556 0.9840 0.8120 0.9800
60 3 6.5 3.3 21 8.9 4.6 0.2715 0.0540 0.6023 0.8166 0.7176
61 14 30.4 16.6 27 11.4 5.9 11.2755 9.7910 0.0008 0.0018 3.4030
40 1 0.4 0.2
44 10 21.7 11.5 41 17.3 9.1 0.5140 0.2574 0.4734 0.6120 1.3280
47 1 2.2 1.1 0
46 3 6.5 3.3 16 6.8 3.4 0.0032 0.0702 0.9546 0.7910 0.9637
48 2 4.3 2.2 6 2.5 1.3 0.4626 0.0377 0.4964 0.8461 1.7500
51 10 21.7 11.5 46 19.4 10.2 0.1317 0.0250 0.7166 0.8723 1.1534
52 9 19.6 10.3 53 22.4 11.9 0.1762 0.0506 0.6746 0.8220 0.8444
54 8 17.4 9.1 43 18.1 9.3 0.0148 0.0078 0.9033 0.9300 0.9500
55 13 5.5 2.8
56 4 1.7 0.9
58 2 0.8 0.4
59 1 2.2 1.1 8 3.4 1.7 0.1806 0.0011 0.6708 0.9728 0.6361
67 7 3.0 1.5
Total 46 237
PF, phenotype frequency; GF, gene frequency.
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Discussion
HLA genetic polymorphisms are race dependent. In a
Japanese population, we were unable to confirm the
relationship between AAA and HLA-DR15 previously
reported African-Americans,6 or results of Hirose in
Japanese AAA patients.6±9 This may be due to small
numbers of patients, differences in methodology (PCR
Table A-3. Phenotype frequency of HLA-DR.
Antigens Patients PF GF Controls PF GF X2 X2c p value p-corrected
value
Odds ratio
1 6 12.2 6.3 31 13.1 6.8 0.0253 0.0057 0.8740 0.9400 0.9227
15 13 26.5 14.3 86 36.3 20.2 1.7077 1.3038 0.1913 0.2535 0.6340
16 4 1.7 0.8
4 27 55.1 33.0 101 42.6 24.2 2.5603 2.0802 0.1096 0.1492 1.6526
11 5 10.2 5.2 15 6.3 3.4 0.9374 0.4363 0.3329 0.5089 1.6818
12 6 12.2 6.3 24 10.1 5.2 0.1941 0.0340 0.6600 0.8537 1.2383
13 7 14.3 7.4 37 15.6 8.1 0.0549 0.0003 0.8148 0.9867 0.9009
14 10 20.4 10.8 36 15.2 7.9 0.8192 0.4782 0.3654 0.4892 1.4316
7 1 2.0 1.0 1 0.4 0.2 1.5325 0.0878 0.2157 0.7670 4.1917
8 10 20.4 10.8 57 24.1 12.9 0.3003 0.1316 0.5837 0.7180 0.8097
9 13 26.5 14.3 59 24.9 13.3 0.0577 0.0035 0.8102 0.9526 1.0895
10 3 1.3 0.6
Total 49 237
PF, phenotype frequency; GF, gene frequency.
Table A-4. Allele frequency of HLA-DR B1.
Antigens Patients PF AF Controls PF AF X2 X2c p value p-corrected
value
Odds ratio
0101 6 12.2 6.3 31 13.1 6.8 0.0252 0.0057 0.8740 0.9400 0.9272
1501 5 10.2 5.2 39 16.5 8.2 1.2191 0.7861 0.2695 0.3752 0.5770
1502 9 18.4 9.7 47 19.8 11.2 0.0553 0.0014 0.8142 0.9702 0.9096
1602 4 1.7 0.8
0301
0302
0401 1 0.4 0.2
0404 1 0.4 0.2
0405 15 30.6 16.7 50 21.1 11.0 2.0933 1.5866 0.1480 0.2078 1.6500
0410 1 2.0 1.0 7 3.0 1.5 0.1244 0.0152 0.7243 0.9020 0.6845
0403 3 6.1 3.1 17 7.2 3.6 0.0689 0.0020 0.7930 0.9640 0.8440
0406 4 8.2 4.2 20 8.4 4.4 0.0040 0.0483 0.9495 0.8261 0.9444
0407 1 2.0 1.0 5 2.1 1.1 0.0009 0.2672 0.9755 0.6052 0.9667
1101 5 10.2 5.2 15 6.3 3.4 0.9374 0.4363 0.3329 0.5089 1.6818
1102
1201 5 10.2 5.2 15 6.3 3.2 0.9374 0.4363 0.3329 0.5089 1.6818
1202 1 2.0 1.0 9 3.8 1.9 0.3713 0.0332 0.5423 0.8554 0.5278
1301 3 6.1 3.1 4 1.7 0.8 3.3445 1.7450 0.0674 0.1865 3.7989
1302 4 8.2 4.2 33 13.9 7.4 1.1964 0.7396 0.2740 0.3898 0.5495
1401 6 12.2 6.3 18 7.6 3.8 1.1421 0.6173 0.2852 0.4321 1.6977
1402
1405 2 4.1 2.1 4 1.7 0.8 1.2482 0.3163 0.2639 0.5739 2.5851
1407 1 0.4 0.2
1403 1 2.0 1.0 5 2.1 1.1 0.0009 0.2672 0.9756 0.6052 0.9667
1406 3 6.1 3.1 8 3.4 1.7 0.8285 0.2522 0.3627 0.6155 1.8668
0701 1 2.0 1.0 1 0.4 0.2 1.5325 0.0878 0.2157 0.7670 4.9167
0803 6 12.2 6.3 36 15.2 8.2 0.2811 0.0952 0.5960 0.7577 0.7791
0801
0802 4 8.2 4.2 21 8.9 4.4 0.0248 0.0145 0.8750 0.9041 0.9143
0804
0811
0901 13 26.5 14.3 59 24.9 13.3 0.0577 0.0035 0.8102 0.9526 1.0895
1001 3 1.3 0.6
Total 49 237
PF, phenotype frequency; AF, Allele frequency.
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here and lymphocytotoxicity assay previously), or dif-
ferent risk factors. Nine of the AAA patients in the
present study also had AIOD. Five of these patients
had HLA-DR B11502 genotype, as compared to four
of 40 AAA patients without AIOD. Interestingly, all
the five patients with HLA-DR B11502 in AIOD-
positive group had HLA-B52. The significance of this
observation is not clear at present and further studies
are needed to clarify this point.
When considering the possible relationship
between HLA and a multifactorial disease such as
AAA, one needs to consider the possibility that not
all patients have a specific HLA type. Since multifac-
torial diseases occur, by definition, due to the exist-
ence of multiple factors, not all patients will have one
specific factor, and not all patients with a specific
factor develop the disease. Even in Takayasu disease
(aortitis syndrome), which is a well-known auto-
immune disease in the cardiovascular field, no signifi-
cant relationship between this disease and class-II
HLA has been recognized. However, its correlation
with class-I HLA of B52 has been confirmed.13±15
In our study, we could not detect significant asso-
ciation with HLA class-II in 49 AAA patients, but did
detect a significant difference in class I molecules,
HLA-A2 and HLA-B61. These data suggest that one
of the genes involved in the pathogenesis of AAA is
located within or near the class-I HLA region. Since
AAA is a multifactorial disease, it is unlikely that the
pathogenetic gene is located only in the HLA region.
In future studies, it will be necessary to perform the
genetic analysis outside of the HLA region, including
those regulating endothelial and platelet functions.
In conclusion, there were significant increases in
HLA-A2 and HLA-B61 frequency in AAA patients
compared to controls. These results are the first to
identify two class-I HLA genes as important genetic
risk factors in the development of AAA in the
Japanese population. We also showed in this study
that both the HLA-B52 antigen and the HLA-DR
B11502 allele were seen more frequently in the AAA
patients with AIOD than those without. We believe
that the risk of developing atherosclerotic diseases
such as IHD in the long term is extremely high in
AAA patients with these HLA genotypes.
Acknowledgment
We thank Drs Taiki Tamaoki and Tomoko Hashimoto-Tamaoki for
their helpful comments and discussion.
References
1 Gregory AK, Yin NX, Capella J, Xia S, Newman KM,
Tilson MD. Feature of autoimmunity in the abdominal aortic
aneurysm. Arch Surg 1996; 131: 85±88.
2 Koch AE, Haines GK, Rizzo RJ et al. Human abdominal aortic
aneurysm: immunophenotypic analysis suggesting an immune
mediated response. Am J Pathol 1990; 137: 1129±1219.
3 Brophy CM, Reilly JM, Smith GJW, Tilson MD. The role of
inflammation in nonspecific abdominal aortic aneurysm disease.
Ann Vasc Surg 1991; 5: 229±233.
4 Bormer JG, Marsh SGE, Albert ED et al. Nomenclature for
factors of the 2HLA system. Tissue Antigens 1995; 46: 1±18.
5 Tomlinson IPM, Bodmer WF. The HLA system and the analysis
of multifactorial genetic disease. Trend Gen 1995; 11: 493±498.
6 Tilson MD, Ozsvath KJ, Hirose H, Xia S. A genetic basis for
autoimmune manifestations in the abdominal aortic aneurysm
resides in the MHC class 2 locus DR B-1. New York Academy of
Sciences 1996; 800: 208±217.
7 Hirose H, Takagi M, Miyagawa M et al Genetic risk factor for
abdominal aortic aneurysm: HLA-DR2(15), A Japanese study.
J Vasc Surg 1998; 500±503.
8 Hirose H, Tilson MD. Negative genetic risk factor for abdom-
inal aortic aneurysm: HLA-DQ3, a Japanese study. J Vasc Surg
1999; 11: 959±960.
9 Albrechtsen D, Solhiem BG, Thorby E. Serological identifica-
tion of five HLA-D associated (Ia-like) determinants. Tissue
Antigens 1977; 9: 153±162.
10 Mukai S, Miyamoto J. Early and mortality after surgical recon-
struction for intra renal abdominal aortic aneurysm associated
with and without aorto iliac occlusive vascular disease. Acta Med
Hyogoensia 1999; 24: 177±185.
11 Kimura A, Sasazuki T. Eleventh International Histocompatibil-
ity Workshop reference protocol for the HLA-typing technique;
HLA 1991.
12 Saito S, Ota S, Hashizumi K, Yamada E. Japanese Normal;
HLA. American Society for Histocompatibility and Immunogenetics
1998; 208±209.
13 Yoshida M, Kimura A, Katsuragi K et al. DNA typing of
HLA-B gene in Takayasu's arteries. Tissue Antigens 1993; 42: 87±90.
14 Kimura A, Kitamura H, Date Y, Numano F. Comprehensive
analysis of HLA genes in Takayasu arteries in Japan. Int J Cardiol
1996; 54: S65±S73.
15 Kimura A, Ota M, Katsuyama Y et al. Mapping of the HLA-
linked genes controlling the susceptibility to Takayasu's arteries.
Int J Cardiol 2000; 75: S105±S110.
Accepted 11 February 2003









HLA-B52 5 #/9 (55.6) 4/37 (10.8) 0.032
HLA-DRB1502 5 #/9 (55.6) 4/40 (10.0) 0.007
# Same patients.
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